QQ客服 官方微博 反馈留言

	Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study
	Xie, Yizhao; Li, Yi; Zhang, Yinbin; Zhang, Shuqun; Li, Wei; Guan, Xiaoxiang; Zhao, Yannan; Gong, Chengcheng; Hu, Xichun; Zhang, Jian
刊名	CLINICAL BREAST CANCER
	2019
卷号	19期号:3
关键词	ER+ HER2(-) breast cancer Endocrine sensitivity Endocrine therapy Fulvestrant Metastatic breast cancer
ISSN号	1526-8209
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3596435
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xie, Yizhao,Li, Yi,Zhang, Yinbin,et al. Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study[J]. CLINICAL BREAST CANCER,2019,19(3).
APA	Xie, Yizhao.,Li, Yi.,Zhang, Yinbin.,Zhang, Shuqun.,Li, Wei.,...&Wang, Biyun.(2019).Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study.CLINICAL BREAST CANCER,19(3).
MLA	Xie, Yizhao,et al."Fulvestrant 500 mg Versus Exemestane in Postmenopausal Women With Metastatic Breast Cancer Resistant to Adjuvant Nonsteroidal Aromatase Inhibitors in Clinical Practice: A Multicenter Retrospective Study".CLINICAL BREAST CANCER 19.3(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。